Previous 10 | Next 10 |
The following slide deck was published by United Therapeutics Corporation in conjunction with this Read more ...
When United Therapeutics (UTHR) signed a deal with MannKind ( MNKD ) for a dry powder inhaled form of Treprostinil, the company also contracted an undisclosed compound within the PAH space. With United's most recent update of its pipeline page, it appears that the undisclosed compound is Adcir...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , March 12, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Martine Rothblatt , Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on t...
Passionate MannKind ( MNKD ) retail investors often contemplate big time buyouts by big pharma, market caps that approach $10 billion, and a situation where the stock goes up to levels which create millionaires. Not a week goes by where there is not some comment about a buyout from Amgen (AMGN...
Arena Pharmaceuticals ( ARNA ) has an estimated $1.3 billion in cash, a billion-dollar licensing deal in the books, and a potential best in class pipeline drug entering phase 3 clinical trials. Simply stated, the company is well positioned, has leverage, and is poised to make some noise in 2...
At the end of the day, a stock is simply a share in the ownership of a business. Stock prices can fluctuate due to a multiplicity of factors in the short term, but over the long term, the stock price and the value of the business tend to move in the same direction. The more profitable the b...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , March 4, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond , Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company...
MannKind ( MNKD ) investors got a little bit of insight regarding its PAH drug candidate TrepT (Dryvaso) from United Therapeutics ( UTHR ) on its Q4 conference call held Wednesday morning. The most important nuggets of information from United Therapeutics which relate to MannKind can be foun...
United Therapeutics Corporation (UTHR) Q4 2018 Results Earnings Conference Call February 27, 2019, 09:00 AM ET Company Participants James Edgemond - Chief Financial Officer Martine Rothblatt - Chairman and CEO Michael Benkowitz - President and COO Jim White - MD, PhD from Unive...
United Therapeutics ( UTHR ) Q4 results : Revenues: $381.4M (-17.9%). More news on: United Therapeutics Corporation, Healthcare stocks news, Earnings news and commentary, Read more ...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...